News
Scientists at the Terasaki Institute for Biomedical Innovation (TIBI), led by Dr. Vadim Jucaud (Assistant Professor), have ...
Effect of cDC2 licensing by CCL5+ Th1 cells following BCL9/BCL9L inhibition on CD8+ T cell cross-priming for enhanced anti-tumor responses. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results